Steroid Receptor Coactivator-Interacting Protein (SIP) Alleviates Ischemic Cerebral Infarction Damage Through the NF-κB Pathway

Abstract

Ischemic stroke leads to high mortality and disability rates in humans. Cerebral ischemic injury has a severe complex pathophysiological mechanism. The abnormal release of inflammatory cytokines will cause brain tissue damage and destroy the blood-brain barrier integrity, which aggravates the process of brain injury. Therefore, attenuating the level of inflammatory response is critical for the therapy of cerebral ischemia injury. This study examined the rule of SIP treatment to support neuron protective effect after cerebral injury in an animal model of middle cerebral artery occlusion (MCAO). After ischemia/reperfusion, neurological function, neuroglia cells activation, infarction volume, brain water content, brain tissue apoptosis ratio, and inflammatory response were assessed, and quantitative PCR and western blot were also detected, respectively. Treatment of SIP ameliorated neurological dysfunction, brain infarction, brain edema, and brain cell apoptosis after MCAO operation. Overexpression SIP also suppressed pro-inflammatory cytokines release. Furthermore, the protective effect of SIP on brain injury occurs through reduced neuroglia cells activation through downregulation of the NF-κB pathway. In summary, the present work indicated that SIP prevents ischemic cerebral infarction-induced inflammation and apoptosis by blocking inflammasome activation via NF-κB signaling pathway. Those results suggest that SIP treatment is an attractive strategy for prevention of ischemic cerebral infarction.

Keywords

ischemic cerebral infarction - steroid receptor coactivator-interacting protein - middle cerebral artery occlusion - inflammation - NF-κB

Publication History

Received: 09 March 2022

Accepted: 20 July 2022

Article published online:
02 September 2022

• References

• 1 Béjot Y, Bailly H, Durier J. et al. Epidemiology of stroke in europe and trends for the 21st century. Presse Méd 2016; 45: e391-e398
• 2 Joffres M, Falaschetti E, Gillespie C. et al. Hypertension prevalence, awareness, treatment and control in national surveys from england, the USA and canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 2013; 3: e003423
• 3 Balch MH, Nimjee SM, Rink C. et al. Beyond the brain: The systemic pathophysiological response to acute ischemic stroke. J Stock 2020; 22: 159
• 4 Pawluk H, Woźniak A, Grześk G. et al. The role of selected pro-inflammatory cytokines in pathogenesis of ischemic stroke. Clin Interv Aging 2020; 15: 469
• 5 Li J, Lu Z, Li W-L. et al. Cell death and proliferation in nf-κb p50 knockout mouse after cerebral ischemia. Brain Res 2008; 1230: 281-289
• 6 Oeckinghaus A, Ghosh S. The nf-κb family of transcription factors and its regulation. Csh Perspect Biol 2009; 1: a000034
• 7 Viatour P, Merville M-P, Bours V. et al. Phosphorylation of nf-κb and iκb proteins: Implications in cancer and inflammation. Trends Biochem Sci 2005; 30: 43-52
• 8 Li Q, Tian Z, Wang M. et al. Luteoloside attenuates neuroinflammation in focal cerebral ischemia in rats via regulation of the pparγ/nrf2/nf-κb signaling pathway. Int Immunopharmacol 2019; 66: 309-316
• 9 Hudson CA, McArdle CA, López Bernal A. Steroid receptor co-activator interacting protein (sip) mediates egf-stimulated expression of the prostaglandin synthase cox2 and prostaglandin release in human myometrium. MHR: Basic Sci Reprod Med 2016; 22: 512-525
• 10 Li L, Li Z-B, Jia M. et al. Therapeutic effects of kank2 in myocardial infarction rats might be associated with the nf-κb p65 inhibition. Int Immunopharmacol 2020; 86: 106687
• 11 Qu M. The neuroprotective effect of steroid receptor coactivator-interacting protein (sip) in astrocyte model of 1-methyl-4-phenylpyridinium (mpp+)-induced parkinson’s disease. Med Sci Monit 2019; 25: 5776-5784
• 12 MacManus JP, Koch CJ, Jian M. et al. Decreased brain infarct following focal ischemia in mice lacking the transcription factor e2f1. Neuroreport 1999; 10: 2711-2714
• 13 Longa EZ, Weinstein PR, Carlson S. et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91
• 14 Hatashita S, Hoff JT, Salamat SM. Ischemic brain edema and the osmotic gradient between blood and brain. J Cereb Blood Flow Metab 1988; 8: 552-559
• 15 Xu S, Zhong A, Ma H. et al. Neuroprotective effect of salvianolic acid b against cerebral ischemic injury in rats via the cd40/nf-κb pathway associated with suppression of platelets activation and neuroinflammation. Brain Res 2017; 1661: 37-48
• 16 Collino M, Aragno M, Mastrocola R. et al. Modulation of the oxidative stress and inflammatory response by ppar-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006; 530: 70-80
• 17 Nanetti L, Taffi R, Vignini A. et al. Reactive oxygen species plasmatic levels in ischemic stroke. Mol Cell Biochem 2007; 303: 19-25
• 18 Zhang Y, Zhang H, Liang J. et al. Sip, a novel ankyrin repeat containing protein, sequesters steroid receptor coactivators in the cytoplasm. EMBO J 2007; 26: 2645-2657
• 19 Mo Z, Tang C, Li H. et al. Eicosapentaenoic acid prevents inflammation induced by acute cerebral infarction through inhibition of nlrp3 inflammasome activation. Life Sci 2020; 242: 117133
• 20 Michinaga S, Koyama Y. Protection of the blood–brain barrier as a therapeutic strategy for brain damage. Biol Pharm Bull 2017; 40: 569-575
• 21 Venkat P, Chopp M, Chen J. Blood – brain barrier disruption, vascular impairment, and ischemia/reperfusion damage in diabetic stroke. J Am Heart Assoc 2017; 6: e005819
• 22 Zhou Y, Gu Y, Liu J. Brd4 suppression alleviates cerebral ischemia-induced brain injury by blocking glial activation via the inhibition of inflammatory response and pyroptosis. Biochem Bioph Res Co 2019; 519: 481-488
• 23 Wang L, Wang P, Dong H. et al. Ulk1/fundc1 prevents nerve cells from hypoxia-induced apoptosis by promoting cell autophagy. Neurochem Res 2018; 43: 1539-1548
• 24 Cho J-W, Lee K-S, Kim C-W. Curcumin attenuates the expression of il-1β, il-6, and tnf-α as well as cyclin e in tnf-α-treated hacat cells; nf-κb and mapks as potential upstream targets. Int J Mol Med 2007; 19: 469-474
• 25 Kułdo JM, Westra J, Ásgeirsdóttir SA. et al. Differential effects of nf-κb and p38 mapk inhibitors and combinations thereof on tnf-α-and il-1β-induced proinflammatory status of endothelial cells in vitro. Am J Physiolcell Ph 2005; 289: C1229-C1239